Samsung Bioepis Confident Eylea And Lucentis Biosimilars Can Coexist

Korea-Based Firm’s Phase III Aflibercept Data Expected This Year

 
• By Dean Rudge
  
Eye
Biosimilars to Lucentis may launch this year, with Eylea biosimilars expected to follow in 2023. • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products